Dulaglutide

Mechanism

A once-weekly GLP-1 injection approved for type 2 diabetes, sold as Trulicity. It links a GLP-1 molecule to an antibody fragment so it stays in your body for about 5 days. Causes moderate weight loss and has proven cardiovascular benefits.

Effects

GLYCEMIC [Tier 1 – FDA-Approved]: Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes. Consists of a GLP-1 analog fused to a modified Fc fragment of human IgG4, extending half-life to ~5 days. Reduces HbA1c by 0.7-1.6% across AWARD trial program. Stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying. WEIGHT LOSS [Tier 1 – FDA-Approved]: Produces modest weight loss of 2-5 kg (4.4-11 lbs) in diabetes trials at 1.5 mg dose. Not FDA-approved for weight management specifically (unlike semaglutide/Wegovy). Weight loss effect is real but substantially less than semaglutide 2.4 mg or tirzepatide. CARDIOVASCULAR [Tier 1 – Human Clinical / FDA Label]: REWIND trial (n=9901): Dulaglutide 1.5 mg reduced major adverse cardiovascular events (MACE) by 12% vs placebo in type 2 diabetes patients. First GLP-1 RA to demonstrate cardiovascular benefit in a population that included patients WITHOUT established cardiovascular disease. Cardiovascular indication added to FDA label. APPETITE / GI [Tier 1 – Human Clinical]: Appetite suppression and nausea are class effects. Nausea incidence approximately 12-21% (dose-dependent), predominantly in first 2-4 weeks of initiation or dose escalation. Diarrhea in ~8-12%. Generally well-tolerated with proper titration. RENAL [Tier 1 – Human Clinical]: REWIND demonstrated slowed decline in eGFR and reduced new macroalbuminuria. Renal protective effects are a class benefit of GLP-1 agonists, and dulaglutide has strong evidence for this.

Practitioner Guide

CLINICAL POSITIONING: Dulaglutide is the "reliable workhorse" GLP-1 agonist. It was the most prescribed GLP-1 RA globally before semaglutide took over. Its key advantages: once-weekly dosing, pre-filled auto-injector (no mixing, no dose dialing — just click and inject), proven cardiovascular benefit, and extensive real-world safety data. Its key limitation: less weight loss than semaglutide or tirzepatide. WHO IS THE IDEAL DULAGLUTIDE PATIENT: • Type 2 diabetics who need glycemic control with modest weight loss. • Patients who are intimidated by injection complexity — Trulicity auto-injector is the simplest GLP-1 device on the market. • Patients with cardiovascular risk factors (REWIND data is compelling). • Patients who tried semaglutide and could not tolerate the GI side effects (dulaglutide is generally milder). • NOT ideal for patients whose primary goal is significant weight loss — semaglutide or tirzepatide are superior for that indication. DOSING: • Starting: 0.75 mg subcutaneous once weekly for 4 weeks. • Maintenance: 1.5 mg once weekly. This is where most patients remain. • Maximum: 4.5 mg once weekly (higher doses approved 2020 for additional glycemic control). Step up: 0.75 → 1.5 → 3.0 → 4.5 mg, with minimum 4 weeks at each dose. • Higher doses (3.0, 4.5 mg) produce more weight loss and glycemic improvement but more GI side effects. TITRATION STRATEGIES TO MINIMIZE NAUSEA: • Never skip the 0.75 mg starting phase. Even patients transferring from another GLP-1 should start at 0.75 mg. • Minimum 4 weeks at each dose level before escalating. Extend to 8 weeks if patient is still experiencing nausea. • Dietary advice during titration: Smaller meals, avoid greasy/heavy foods, eat slowly, stop when feeling "satisfied not full." • Hydration: 64+ oz water daily. Dehydration worsens nausea. • If nausea persists beyond 8 weeks at a dose, that may be the patient maximum tolerated dose. Do not force-escalate. • Ginger capsules (250 mg with meals), peppermint tea, and anti-nausea bands can help mild cases. • Ondansetron (Zofran) 4 mg for breakthrough nausea — use sparingly, as it can cause constipation (compounding the GLP-1 constipation effect). TRANSITIONING BETWEEN GLP-1 AGENTS: • Dulaglutide → Semaglutide: Common transition when more weight loss needed. Stop dulaglutide, start semaglutide 0.25 mg the following week. Still titrate semaglutide slowly — GLP-1 receptor tolerance from dulaglutide does NOT fully transfer. Expect some nausea at each new semaglutide dose level. • Semaglutide → Dulaglutide: Uncommon but occurs when semaglutide GI effects are intolerable. Stop semaglutide, wait 2 weeks (long half-life washout), start dulaglutide 0.75 mg. Can often escalate to 1.5 mg faster since patient has GLP-1 receptor conditioning. • Exenatide → Dulaglutide: Stop exenatide, start dulaglutide 0.75 mg the next week. MUSCLE PRESERVATION DURING WEIGHT LOSS: • Protein: Minimum 1.0 g/kg goal body weight/day. Target 1.2-1.5 g/kg if tolerated. GLP-1 agonists suppress appetite, so protein must be prioritized in the reduced caloric intake. • Resistance training: 2-3x/week minimum. Progressive overload. This is the single most important intervention for lean mass preservation. • Creatine monohydrate 5 g/day: Supports muscle performance and may attenuate lean mass loss. • Leucine-rich protein sources or supplemental leucine (2-3 g/meal) to maximize muscle protein synthesis per meal. • Monitor: Body composition (DEXA scan at baseline and every 3-6 months if available). If lean mass dropping disproportionately, intensify resistance training and increase protein. MANAGING "GLP-1 FACE": • Rapid facial fat loss causing gaunt, aged appearance — more common with aggressive weight loss. • Prevention: Slow, steady weight loss (1-2 lbs/week target). Adequate protein. Resistance training. • If occurring: Consider slowing weight loss rate by reducing GLP-1 dose to maintenance rather than maximum. • Dermal fillers (hyaluronic acid) and collagen-stimulating treatments can address cosmetic concerns. • Collagen peptide supplementation (10-15 g/day) may support skin elasticity, though evidence is modest. COMPOUNDING vs BRAND: • Dulaglutide is NOT on the FDA shortage list (unlike semaglutide/tirzepatide), so compounding pharmacies cannot legally compound it under 503B exemptions. • Patients must use brand Trulicity. Insurance coverage is generally good for T2D indication. • GoodRx cash price approximately $800-1000/month without insurance. WHAT HAPPENS WHEN PATIENTS STOP: • Weight regain is expected. AWARD trials showed weight returns toward baseline within 6-12 months of discontinuation. • HbA1c rises back to pre-treatment levels. • Appetite returns gradually over 2-4 weeks as GLP-1 receptor signaling wanes. • Critical: Patients should have a maintenance plan BEFORE stopping — caloric targets, exercise routine, behavioral strategies. • Some practitioners taper rather than abrupt discontinuation: 1.5 mg → 0.75 mg for 4-8 weeks → stop. No evidence this prevents rebound, but may ease the psychological transition.

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  GLP-1 receptor agonists are associated with increased pancreatitis risk. Dulaglutide (Trulicity) prescribing information contraindicates use with history of pancreatitis.
  Action: Do not use. Contraindication per prescribing information.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  Dulaglutide causes thyroid C-cell tumors in rodents. BLACK BOX WARNING: Contraindicated with personal or family history of MTC or MEN2.
  Action: Absolutely contraindicated. Do not use. Black box warning per Trulicity labeling.
• hard stop — Pregnancy
  Animal studies showed adverse developmental effects at high doses. No adequate human data. Weight loss during pregnancy may cause fetal harm.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy.
• hard stop — Breastfeeding
  Insufficient data on excretion in human breast milk. Risk-benefit does not support use.
  Action: Do not use while breastfeeding.
• hard stop — Gastroparesis
  GLP-1 agonists delay gastric emptying. Contraindicated in patients with gastroparesis.
  Action: Do not use in patients with diagnosed gastroparesis.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use.
  Action: Do not provide to individuals under 18.
• hard stop — Other GLP-1 receptor agonists
  Concurrent use of multiple GLP-1 receptor agonists causes dangerous additive effects.
  Action: Never combine multiple GLP-1 agonists. Ensure adequate washout before switching.
• requires physician — Insulin
  Concurrent use with insulin significantly increases risk of hypoglycemia.
  Action: Requires physician supervision. Insulin dose reduction typically required. Frequent blood glucose monitoring.
• requires physician — Sulfonylureas
  Combined use increases severe hypoglycemia risk.
  Action: Sulfonylurea dose reduction required before initiating. Blood glucose monitoring mandatory.
• caution — Gallbladder disease
  GLP-1 agonists are associated with cholelithiasis and cholecystitis, likely related to weight loss effects.
  Action: Monitor for gallbladder symptoms. Use with caution in patients with gallstone history.

Evidence

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

  Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Munoz Velandia OM, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T (2019) — The Lancet — PMID: 31189511

  Dulaglutide 1.5 mg weekly reduced MACE by 12% vs placebo (HR 0.88, 95% CI 0.79-0.99) over a median 5.4 years in T2D patients with and without established CVD. Notably included a broader population (31% with prior CV events) than prior GLP-1 RA CVOTs. Significant reduction in non-fatal stroke. HbA1c reduced by 0.61% more than placebo.

  strong

Research Summary

TIER 1 (Human Clinical Trials / FDA-Approved): • AWARD Trial Program (12+ trials): Comprehensive Phase III evaluation. AWARD-1 through AWARD-11 plus extensions. Demonstrated HbA1c reductions 0.7-1.6%, weight loss 2-5 kg, superiority over sitagliptin, metformin, and insulin glargine for glycemic control. • REWIND (Gerstein et al., 2019, Lancet): Cardiovascular outcomes trial, n=9901. 12% reduction in MACE (HR 0.88, CI 0.79-0.99). First GLP-1 RA to show CV benefit in a population including primary prevention patients. Median follow-up 5.4 years. • Renal outcomes from REWIND: Significant reduction in composite renal endpoint (new macroalbuminuria + sustained eGFR decline + renal replacement therapy). • FDA approvals: Type 2 diabetes (2014), cardiovascular risk reduction indication added (2020), higher doses (3.0 mg, 4.5 mg) approved 2020. TIER 2 (Limited Human / Strong Preclinical): • AWARD-11: Higher doses (3.0, 4.5 mg) showed additional HbA1c reduction (-0.2 to -0.3% vs 1.5 mg) and weight loss (-1 to -2 kg additional vs 1.5 mg). • Real-world effectiveness studies confirming trial results translate to clinical practice. • Comparative effectiveness meta-analyses showing dulaglutide slightly less effective than semaglutide for weight loss but comparable for glycemic control. TIER 3 (Preclinical / Mechanistic): • Fc fusion protein pharmacology: IgG4 Fc fragment provides long half-life without receptor-mediated clearance typical of native GLP-1. • Neuroprotective effects in animal models (GLP-1R activation in brain). • Anti-inflammatory properties via GLP-1R signaling in macrophages and hepatocytes. EVIDENCE GAPS: No dedicated weight loss indication trial (unlike STEP for semaglutide or SURMOUNT for tirzepatide). Head-to-head with semaglutide for weight loss not comprehensively studied. Long-term data beyond 5 years limited. Effect on lean body mass specifically not well-characterized in AWARD program.